LEQEMBI
LEQEMBI (Lecanemab-irmb) is an FDA-approved monoclonal antibody infusion therapy developed for the treatment of early Alzheimer’s disease, including mild cognitive impairment and mild dementia stages. Each single-dose, preservative-free 1×5 mL vial contains Lecanemab-irmb, which selectively binds to soluble and insoluble amyloid-beta aggregates — helping to clear amyloid plaques from the brain and slow cognitive decline.
Administered intravenously (IV) under professional supervision every two weeks, LEQEMBI offers a breakthrough approach in managing Alzheimer’s by addressing one of the underlying causes rather than only the symptoms.
InfusionMed USA, headquartered in Carrollton, Texas, supplies LEQEMBI to licensed clinics, infusion centers, and hospitals throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We provide secure cold-chain logistics, verified sourcing, and timely delivery for all Alzheimer’s infusion medications.
For IV infusion use only. Store at 2°C–8°C (36°F–46°F). Do not freeze or shake.
Download Form